Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Neoplasms 7Multiple Myeloma 7Lymphoma 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, T-Cell, Cutaneous 4Mycosis Fungoides 3Sezary Syndrome 2Recurrence 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Immunoproliferative Disorders 2Immune System Diseases 2Vascular Diseases 1Stage IIIB or IV Non-Small Cell Lung Cancer 1Paraproteinemias 1Pancreatic Neoplasms 1Neuroectodermal Tumors 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Mesothelioma 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1

Interventions

Vorinostat 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Stage IIIB or IV Non-Small Cell Lung Cancer × Vorinostat × Clear all
NCT00473889 2015-07-03

A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)

Merck Sharp & Dohme LLC

Phase 2/3 Terminated
253 enrolled 13 charts
Thoracic

Stage IIIB or IV Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡